In NAC Docket, NAD+ Drug Firm Suggests US FDA Get Serious About Dietary Ingredient Regulations

MetroBiotech argues it and other drug developers and manufacturers are harmed as FDA allows NAD+ use in dietary supplements without requiring new dietary ingredient notifications and despite DSHEA’s preclusion clause.